Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17744840 | 0.89 | SMN1; SMN2 (0.71) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL16430749 | 0.87 | NPSR1 (0.69) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL3774866 | 0.84 | MEN1 (0.63) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL8522632 | 0.84 | HDAC1 (0.72) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL864819 | 0.84 | MEN1 (1.00) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL18147885 | 0.84 | SMN1; SMN2 (0.78) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL17744830 | 0.83 | SMN1; SMN2 (0.68) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL16444873 | 0.82 | HDAC1 (0.69) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL11306035 | 0.82 | NPC1 (0.71) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL29513264 | 0.82 | HDAC1 (0.69) | NPSR1SMN1; SMN2HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| US-4094636-A | DIAZOTIZATION | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | NPSR1 1563/4885SMN1; SMN2 1085/4885HSD17B10 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.